CompletedNCT02035553
Pimavanserin Compared With Placebo for Psychosis in Alzheimer’s Disease
About this title
A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis
Read the official source — NCT02035553Medication studyAges 50+United KingdomSchizophrenia
Understand this study
Who was this study for?
Listed age limits: from 50 years.
- Listed locations
- LondonSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateNovember 2013
- Recruitment status
- Completed
- Enrollment listed in the registry
- 181
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United Kingdom
- Age range
- Over 50 Years
- Official registry ID
- NCT02035553
- Official title
Show the full official title
A Single Center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer's Disease
Get this study by email
Recruitment & locations
CompletedLondon
Questions about this study
Who is behind this study?
The study sponsor is ACADIA Pharmaceuticals Inc.
Did this study involve medication?
Yes. The study involved medication, including Pimavanserin tartrate and Placebo.
Who was this study for?
Listed age limits: from 50 years.
Want to explore more studies?
Explore studiesRelated studies
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...
Long-Term Safety of EVP-6124 Added to Schizophrenia Medication